Genky DrugStores Co., Ltd. (9267) AI Stock Analysis

• Market Cap: ¥138.75B
• Dividend Yield: 0.29%
• Average Volume (3M): 93.42K
• Price to Earnings (P/E): 19.4
• Beta (1Y): 0.14
• Revenue Growth: 8.62%
• EPS Growth: 11.68%
• Country: JP
• Employees: 1,661
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 72.17
• Shares Outstanding: 30,996,967
• 10 Day Avg. Volume: 107,110
• 30 Day Avg. Volume: 93,423
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: ¥4,962.00 ▲(9.78% Upside)

Genky DrugStores Co., Ltd. demonstrates strong financial fundamentals with significant revenue and profit growth, supported by improved cash flows and equity position. Technical indicators suggest bullish momentum, though caution is advised due to overbought signals. The valuation is reasonable, but the low dividend yield may deter income investors.

Genky DrugStores Co., Ltd. Business Overview & Revenue Model

Company Description

Genky DrugStores Co., Ltd. (9267) is a Japanese company operating in the retail sector, primarily focused on the pharmacy and drugstore market. It provides a wide range of products including pharmaceuticals, cosmetics, daily necessities, food, and other household items. The company is known for its expansive network of stores across Japan, offering a convenient shopping experience for customers seeking healthcare and lifestyle products.

How the Company Makes Money

Genky DrugStores Co., Ltd. generates revenue through the sale of a diverse array of products in its retail stores. Its primary revenue streams include the sale of pharmaceuticals, over-the-counter medicines, health and beauty products, and everyday consumer goods. The company capitalizes on its extensive store network and strategic locations to attract a steady flow of customers. Additionally, Genky DrugStores may engage in partnerships with suppliers and leverage bulk purchasing to optimize inventory costs and enhance profit margins. The company's focus on customer satisfaction and competitive pricing also plays a crucial role in maintaining its market position and driving sales.

Genky DrugStores Co., Ltd. Financial Statement Overview

Summary

Genky DrugStores Co., Ltd. presents a strong financial profile with robust revenue and profitability growth. Improved leverage and equity position reflect a stable financial foundation, and strong operating cash flows indicate effective cash management. However, the high level of debt remains a potential risk.

Income Statement

Genky DrugStores Co., Ltd. has demonstrated strong revenue growth, with a consistent increase from ¥103.9 billion in 2019 to ¥184.9 billion in 2024, reflecting a robust growth trajectory. The gross profit margin improved from 23.5% in 2019 to 20.3% in 2024, indicating enhanced cost management. The company's net profit margin has also improved significantly, rising from 2.6% in 2019 to 3.4% in 2024, showing improved profitability. However, the EBIT margin saw moderate growth, indicating room for further operational efficiency improvements.

Balance Sheet

The company's debt-to-equity ratio decreased slightly over the years, reflecting a moderate leverage position with a ratio of approximately 0.66 in 2024, down from 0.87 in 2019. Stockholders' equity has shown consistent growth, supporting a solid equity ratio of 40.9% in 2024. The return on equity (ROE) improved from 10.7% in 2019 to 13.5% in 2024, indicating improved returns for shareholders. Despite the overall positive trends, the high level of total debt remains a potential risk.

Cash Flow

Genky DrugStores has shown a strong increase in operating cash flow, with a growth from ¥4.3 billion in 2019 to ¥13.3 billion in 2024, indicating strong cash generation capabilities. The free cash flow has turned positive to ¥2.8 billion in 2024 from a negative position in previous years, reflecting better capital expenditure management. However, the free cash flow to net income ratio indicates that the company could further improve its cash flow efficiency.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	184.86B	169.06B	154.64B	142.38B	123.60B
Gross Profit	37.62B	34.55B	30.95B	30.29B	26.71B
EBITDA	14.47B	11.73B	10.73B	10.78B	7.86B
Net Income	6.32B	4.76B	4.42B	4.83B	2.76B
Balance Sheet
Total Assets	113.94B	105.91B	97.12B	90.80B	83.15B
Cash, Cash Equivalents and Short-Term Investments	5.90B	5.33B	5.44B	7.91B	6.62B
Total Debt	30.65B	32.35B	30.96B	28.56B	30.39B
Total Liabilities	67.26B	65.23B	60.88B	58.63B	55.46B
Stockholders Equity	46.68B	40.68B	36.23B	32.17B	27.69B
Cash Flow
Free Cash Flow	2.81B	-1.16B	-4.43B	3.12B	-3.59B
Operating Cash Flow	13.26B	8.77B	6.08B	12.08B	7.41B
Investing Cash Flow	-10.63B	-9.74B	-10.59B	-8.83B	-11.22B
Financing Cash Flow	-2.06B	854.00M	2.04B	-1.95B	7.99B

Genky DrugStores Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4520.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Positive. The current price of 4520 is above the 20-day moving average (MA) of 4164.50, above the 50-day MA of 3842.25, and above the 200-day MA of 3291.44, indicating a bullish trend. The MACD of 154.60 indicates Negative momentum. The RSI at 77.60 is Negative, neither overbought nor oversold. The STOCH value of 77.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9267.

Genky DrugStores Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3549	76 Outperform	¥432.05B	23.44		0.34%	14.79%	35.84%
7649	75 Outperform	$696.42B	16.27	16.26%	0.95%	20.18%	82.36%
9267	74 Outperform	¥138.75B	19.44		0.29%	8.62%	11.68%
3141	74 Outperform	¥535.77B	29.19		1.40%	7.43%	-24.81%
9989	73 Outperform	¥532.59B	17.33	11.61%	2.85%	6.66%	5.56%
3391	71 Outperform	¥547.77B	25.09	4.93%	2.40%	4.63%	-47.30%
Sector *	65 Neutral	¥351.75B	9.37	-3.15%	2.47%	11.67%	-10.80%

Genky DrugStores Co., Ltd. Corporate Events

Genky DrugStores Reports Strong Financial Growth with Positive Outlook

Genky DrugStores Co., Ltd. reported an 8.6% increase in net sales for the fiscal year ending June 20, 2025, with net income attributable to owners rising by 11.7%. Despite a decrease in dividend payout ratio, the company’s financial position strengthened with an increase in total assets and net assets. The company forecasts continued growth in net sales and income for the fiscal year ending June 20, 2026, indicating a positive outlook for stakeholders.